LAMC2 and neoplasm: Intriguingly, targeting the tumor bulk cells as well as LAMC2-high TICs with Vactosertib, a new specific inhibitor of the TGF-β receptor type 1 (TGFBR1), efficiently inhibited PDAC progression and abrogated metastasis.